De Kuan C.
About De Kuan C.
De Kuan C. is a Senior Director at Sana Biotechnology, Inc., focusing on innovative techniques and drug candidates for cancer therapy. With extensive experience in immunotherapy and bispecific antibody engineering, he has held various positions in notable institutions including Juno Therapeutics and Dana-Farber Cancer Institute.
Work at Sana Biotechnology
Currently, De Kuan C. serves as Senior Director at Sana Biotechnology, Inc., a position held since 2020. In this role, he focuses on discovering new techniques and drug candidates specifically for cancer therapy. His leadership contributes to the advancement of innovative approaches in the field of oncology.
Education and Expertise
De Kuan C. holds a Doctor of Philosophy (Ph.D.) in Pathology/Experimental Pathology from National Taiwan University. He also studied English Language and Literature at Northeastern University. His expertise includes bispecific antibody engineering and T cell immunity manipulation, which are critical areas in cancer research and therapy.
Background
Before joining Sana Biotechnology, De Kuan C. accumulated extensive experience in the field of immunotherapy and cell therapy. He worked at Juno Therapeutics, Inc. as a Scientist in Cell Therapy for nine months in 2016. He also held various positions, including Consultant at Tikcro Technologies and Associate Director at Takeda, where he focused on immune checkpoint inhibitors and cell therapy.
Research Experience
De Kuan C. has a robust background in research, having served as a Research Fellow in Immunotherapy at Dana-Farber Cancer Institute from 2010 to 2015. He also worked as a Postdoctoral Research Fellow in Drug Delivery at Academia Sinica for two months in 2009. His research has involved oncology animal model development and humanized animal model research, contributing to advancements in cancer treatment.
Professional Roles Prior to Sana Biotechnology
Prior to his current role, De Kuan C. held significant positions in academia and industry. He was an Instructor in Medicine at Harvard Medical School from 2015 to 2016, focusing on Immuno-Oncology. His diverse experiences across various organizations have equipped him with a comprehensive understanding of cancer therapy and research.